EN PL

FDA: Guidance for Industry Immunogenicity - Related Considerations for the Approval of Low Molecular Weight Heparin for NDAs and ANDAs

10.04.2014
This draft guidance discusses immunogenicity - related approval considerations for low molecular weight heparin (LMWH) products.